Connective Tissue Disease–Associated Interstitial Lung Disease (CTD-ILD)
Connective Tissue Disease–Associated Interstitial Lung Disease (CTD-ILD)
- What is connective tissue disease–associated interstitial lung disease (CTD-ILD)?
CTD-ILD is a lung complication of autoimmune rheumatic diseases in which inflammation and/or fibrosis affects the tissue surrounding the air sacs. It may cause progressive breathing difficulty and impaired lung function.
- Which connective tissue diseases are commonly associated with ILD?
ILD can occur with systemic sclerosis (scleroderma), rheumatoid arthritis, inflammatory myositis, Sjögren syndrome, mixed connective tissue disease, and systemic lupus erythematosus. The frequency and pattern of lung involvement vary among these diseases.
- What are the common symptoms of CTD-ILD?
The most common symptoms are shortness of breath, especially during activity, and persistent dry cough. Some patients may also experience fatigue, reduced exercise capacity, or chest discomfort.
- Can ILD occur without obvious breathing symptoms?
Yes. Early or mild ILD may produce few or no symptoms and may be detected during evaluation of the underlying connective tissue disease. This is why appropriate screening is important in patients at increased risk.
- How is CTD-ILD diagnosed?
Diagnosis usually involves clinical assessment, high-resolution CT (HRCT) of the chest and pulmonary function tests (PFTs). Blood tests, oxygen assessment, echocardiography, and other investigations may be used depending on the clinical situation.
- Is CTD-ILD a serious condition?
CTD-ILD can range from mild and stable disease to progressive pulmonary fibrosis. Early recognition and regular monitoring help identify patients who require treatment before significant loss of lung function occurs.
- How is CTD-ILD treated?
Treatment depends on the underlying autoimmune disease, severity, and whether the ILD is progressing. Depending on the individual case, treatment may include immunosuppressive therapy and/or antifibrotic treatment, along with supportive measures.
- Can CTD-ILD be completely cured?
Established lung fibrosis may not be completely reversible, but treatment can often control inflammation, slow disease progression, preserve lung function, and improve symptoms. Outcomes vary considerably among patients.
- How is CTD-ILD monitored over time?
Patients are usually followed with symptom assessment and pulmonary function tests, particularly FVC and DLCO. HRCT and other investigations may be repeated when clinically indicated to assess progression or response to treatment.
- What can patients do to protect their lungs?
Patients should avoid smoking, remain physically active as advised, receive appropriate vaccinations, take prescribed medicines regularly, and attend scheduled follow-up visits. New or worsening breathlessness, persistent cough, or reduced exercise tolerance should be discussed promptly with the treating rheumatologist.
.png)
